Treatment Approaches in Advanced RCC


ASCO® 2023 Insights: "FGFR3 Alterations in Phase III PROOF 302 Trial: Infigratinib (BGJ398) as Adjuvant Therapy in Patients With Invasive Urothelial Carcinoma"

174 views
June 6, 2023
0 Comments
Login to view comments. Click here to Login